GlassScriptPhysician profile
Lionel Herrera
NPI 1255366506
$1,391.66
in general payments reported to CMS, 2019-2025
15 companies · $458 in 2025
The $458 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.23 · 2022: $76.63 · 2023: $376 · 2024: $410 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $206.11 | 2021-2024 | Auvi-Q |
| Kowa Pharmaceuticals America, INC. | $189.23 | 2025 | Zoryve |
| Genzyme Corporation | $175.34 | 2023-2024 | |
| Pfizer INC. | $152.25 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $143.92 | 2025 | |
| Glaxosmithkline, LLC. | $111.67 | 2021-2025 | Bexsero, Pediarix |
| Astrazeneca Pharmaceuticals LP | $82.15 | 2023-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $81.33 | 2022-2025 | Flucelvax |
| Merck Sharp & Dohme LLC | $69.19 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Aimmune Therapeutics, INC. | $54.89 | 2023 | |
| Sanofi Pasteur INC. | $50.42 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $29.55 | 2023 | Dupixent |
| Phadia US INC. | $16.97 | 2024 | Immunocap |
| Amgen INC. | $15.67 | 2024 | Actimmune |
| Horizon Therapeutics Plc | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lionel Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.